marketwatch_top

Big Tech’s AI build-out needs these 3 companies to keep the lights on — and they’re cashing in

the real money in ai isn't in the apps — it's in the industrial backbone keeping the lights on. three companies are cashing in as big tech pours capital into agentic ai infrastructure.

these firms supply the physical gear — power systems, cooling, and grid equipment — that hyperscalers need to run their data centers. the headlines chase software, but the revenue is flowing to the boring stuff: transformers, switchgear, and backup generators. each of the three has reported double-digit order growth tied directly to ai build-out contracts.

one makes electrical distribution equipment and saw its data center backlog hit a record last quarter. another builds modular power solutions and has locked in multi-year deals with three of the four biggest cloud providers. the third specializes in thermal management and just opened a new factory to meet demand. none of them are household names. all of them are raising guidance.

source: marketwatch_top
sentiment: +0.60 · impact: 0.70

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds